» Articles » PMID: 19360131

Elite Suppressor-derived HIV-1 Envelope Glycoproteins Exhibit Reduced Entry Efficiency and Kinetics

Overview
Journal PLoS Pathog
Specialty Microbiology
Date 2009 Apr 11
PMID 19360131
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Elite suppressors (ES) are a rare subset of HIV-1-infected individuals who are able to maintain HIV-1 viral loads below the limit of detection by ultra-sensitive clinical assays in the absence of antiretroviral therapy. Mechanism(s) responsible for this elite control are poorly understood but likely involve both host and viral factors. This study assesses ES plasma-derived envelope glycoprotein (env) fitness as a function of entry efficiency as a possible contributor to viral suppression. Fitness of virus entry was first evaluated using a novel inducible cell line with controlled surface expression levels of CD4 (receptor) and CCR5 (co-receptor). In the context of physiologic CCR5 and CD4 surface densities, ES envs exhibited significantly decreased entry efficiency relative to chronically infected viremic progressors. ES envs also demonstrated slow entry kinetics indicating the presence of virus with reduced entry fitness. Overall, ES env clones were less efficient at mediating entry than chronic progressor envs. Interestingly, acute infection envs exhibited an intermediate phenotypic pattern not distinctly different from ES or chronic progressor envs. These results imply that lower env fitness may be established early and may directly contribute to viral suppression in ES individuals.

Citing Articles

The evolution of envelope function during coinfection with phylogenetically distinct human immunodeficiency virus.

Omar S, Woodman Z BMC Infect Dis. 2024; 24(1):934.

PMID: 39251948 PMC: 11385138. DOI: 10.1186/s12879-024-09805-z.


Replicative fitness and pathogenicity of primate lentiviruses in lymphoid tissue, primary human and chimpanzee cells: relation to possible jumps to humans.

Tebit D, Nickel G, Gibson R, Rodriguez M, Hathaway N, Bain K EBioMedicine. 2024; 100:104965.

PMID: 38215691 PMC: 10827413. DOI: 10.1016/j.ebiom.2023.104965.


Contribution of the HIV-1 Envelope Glycoprotein to AIDS Pathogenesis and Clinical Progression.

Valenzuela-Fernandez A, Cabrera-Rodriguez R, Casado C, Perez-Yanes S, Pernas M, Garcia-Luis J Biomedicines. 2022; 10(9).

PMID: 36140273 PMC: 9495913. DOI: 10.3390/biomedicines10092172.


Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 Envelope.

Ratcliff A, Venner C, Olabode A, Knapp J, Pankrac J, Derecichei I J Virol. 2022; 96(14):e0185121.

PMID: 35862673 PMC: 9327689. DOI: 10.1128/jvi.01851-21.


Omic Technologies in HIV: Searching Transcriptional Signatures Involved in Long-Term Non-Progressor and HIV Controller Phenotypes.

De La Torre-Tarazona E, Ayala-Suarez R, Diez-Fuertes F, Alcami J Front Immunol. 2022; 13:926499.

PMID: 35844607 PMC: 9284212. DOI: 10.3389/fimmu.2022.926499.


References
1.
Tersmette M, Gruters R, de Wolf F, de Goede R, Lange J, Schellekens P . Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol. 1989; 63(5):2118-25. PMC: 250628. DOI: 10.1128/JVI.63.5.2118-2125.1989. View

2.
Deacon N, Tsykin A, Solomon A, Smith K, Hooker D, McPhee D . Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science. 1995; 270(5238):988-91. DOI: 10.1126/science.270.5238.988. View

3.
Labrosse B, Labernardiere J, Dam E, Trouplin V, Skrabal K, Clavel F . Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J Virol. 2002; 77(2):1610-3. PMC: 140831. DOI: 10.1128/jvi.77.2.1610-1613.2003. View

4.
Platt E, Durnin J, Kabat D . Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J Virol. 2005; 79(7):4347-56. PMC: 1061535. DOI: 10.1128/JVI.79.7.4347-4356.2005. View

5.
Li B, Gladden A, Altfeld M, Kaldor J, Cooper D, Kelleher A . Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J Virol. 2006; 81(1):193-201. PMC: 1797245. DOI: 10.1128/JVI.01231-06. View